[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pasc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pasc":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,76,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100544272","phase-2-lift-life-improvement-trial-100544272",false,"NCT06366724","LIFT: Life Improvement Trial","LIFT","Inclusion Criteria:\n\n1. Meet National Academy of Medicine Criteria, Canadian Consensus Criteria (See appendix), and demonstrate orthostatic intolerance for diagnosis of ME\u002FCFS\n2. Participant is ≥ 18 and ≤ 70 years of age at screening, inclusive.\n3. The onset of symptoms prior to December 2023.\n4. Female participant is not pregnant and at least 1 of the following conditions apply:\n\n   1. Not a woman of childbearing potential\n   2. Woman of childbearing potential who agrees to follow the contraceptive guidance. from the time of informed consent.\n5. Participant agrees and can adhere to the study requirements for the length of the study.\n6. Participant has a body mass index (BMI) range of 17 to 40 kg\u002Fm2, inclusive.\n7. Participant agrees not to participate in another interventional study while participating in the present study.\n8. Participant has a functioning smart phone to download and run the DANA Brain Vital Mobile Application.\n\nExclusion Criteria:\n\n1. Pregnant, planning to become pregnant, or breastfeeding.\n2. Any use of opioid medications within 30 days of screening.\n3. Positive urine test for opioids\n4. History of alcohol, opioid or other substance misuse\n5. Participation in another interventional clinical trial in the last 30 days or planned during the trial period.\n6. Allergy to medication components\n7. Participant has any condition which, in the investigator's opinion, makes the participant unsuitable for study participation.\n8. Participant has diabetes mellitus (type 1 or 2).\n9. Participant has undergone an inpatient hospitalization within the 30 days prior to the randomization or has a planned hospitalization or a surgical procedure during the study, which may affect the study assessments, in the opinion of the investigator.\n10. Participant has clinically significant respiratory disease (such as chronic obstructive pulmonary disease, cystic fibrosis, severe asthma, lung infections including tuberculosis, sarcoidosis, thoracic endometriosis, pulmonary fibrosis, and lung cancers) and\u002For cardiac disease (medical history or current clinical findings)\n11. Participant has an active malignancy or any other cancer.\n12. Participant has initiated an exercise regimen within 4 weeks prior to randomization.","ALL","18 Years","70 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The LIFT will be conducted at Brigham and Women's Hospital (BWH) of Harvard Medical School, focusing on the effect of Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) in subjects aged 18-70 meeting the Canadian consensus criteria (CCC) for Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS) as well as having specifically Orthostatic Intolerance (OI). Long COVID (LC) subjects will also be included if they meet CCC and have OI.\n\nThis double-blind, placebo-controlled study will involve 160 participants randomized into one of four possible groups: Pyridostigmine\u002FLDN (40), Pyridostigmine\u002FPlacebo (40), LDN\u002FPlacebo (40), Placebo\u002FPlacebo (40). The dose of Pyridostigmine will be carefully titrated from 30mg to 60mg three times a day, and the dose of LDN will be titrated from 1.5 mg to 4.5 mg once daily.\n\nThe trial includes a scale-back plan, allowing participants to reduce their dosage if they experience intolerance symptoms, with adjustments made during weekly visits. This plan provides a personalized approach to medication tolerance, ensuring participant's safety and comfort throughout the trial.\n\nThe time commitment for the participant is approximately three (3) months, and during this time, there will be three (3) in-person visits to BWH and four (4) virtual visits. Study procedures will include two (2) submaximum cardiopulmonary exercise tests, questionnaires (virtually completed), and blood and urine collection. We will be recruiting from the BWH Dyspnea Clinic as well as the Open Medicine Foundation (OMF) StudyME Registry and anticipate the entire trial will take two (2) years to complete.\n\nThe LIFT represents a significant endeavor to improve treatment options for ME\u002FCFS patients and contribute to the broader understanding of this debilitating condition.",[27,28,29],"ME\u002FCFS","Long COVID","PASC",[31,32,33,34,35,36,28],"Chronic fatigue","Mestinon","Low Dose Naltrexone","Orthostatic Intolerance","Post exertional malaise","Cognitive Impairment","RECRUITING","2025-10-21",{"date":40,"type":41},"2025-10-22","ACTUAL",{"date":43,"type":41},"2024-09-10",{"date":45,"type":21},"2026-11",{"name":47,"class":48},"Brigham and Women's Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":49},"100588377","phase-2-magnetic-resonance-analysis-of-neural-inflammatory-factors-and-external-stimulation-100588377","NCT06940609","Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation","Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation (MANIFEST)","MANIFEST","Inclusion Criteria:\n\n1. aged 18-80\n2. a documented diagnosis of PASC with evidence of ongoing symptoms as demonstrated by score of 12 on the NIH RECOVER Symptom List\n3. have \"brain fog\" or cognitive difficulties as one of the ongoing symptoms\n4. are fluent in English\n5. if taking psychotropic medications, have been on stable doses for the past month.\n\nExclusion Criteria:\n\n1. a prior history of other neurological disease, or any history of seizures, so as to reduce risk of exacerbation of epilepsy or other neurological symptoms;\n2. history of a psychotic disorder, such as schizophrenia or bipolar disorder, so as to reduce risk of psychiatric decompensation\n3. history of ongoing substance\u002Falcohol dependence, to reduce confounding effects on diagnosis and brain imaging\n4. presence of any implanted electrical device (e.g., pacemaker), to reduce risk of device malfunction from rTMS\n5. recent medical hospitalization (within four weeks), to reduce risk of medical decompensation during the study\n6. any condition that would prevent the subject from completing the protocol\n7. appointment of a legal representative, to avoid coercion of a vulnerable population\n8. any ongoing litigation related to medical diagnosis, or disability, to prevent interference with legal proceedings\n9. any contraindication to MRI\n10. membership in an identified vulnerable population, including minors, pregnant women, and prisoners, so as to prevent coercion.","80 Years",{"count":60,"type":21},60,[24],"The goal of this clinical trial is to test whether a type of rapid outpatient brain stimulation that uses magnetic fields, called accelerated intermittent theta burst stimulation (iTBS), can treat symptoms such as brain fog, depression, and anxiety in patients with Long COVID. The main questions it aims to answer are:\n\n* Is iTBS effective and feasible for reducing Long COVID symptoms? We will measure these symptoms using the Symptom Burden Questionnaire.\n* Are there changes in inflammatory brain chemicals associated with treatment with iTBS? We will be looking at levels of choline in the brain, which is thought to be related to inflammation.\n\nResearchers will compare sham versus active forms of iTBS to see if the active group has greater improvement in symptoms.\n\nParticipants will complete symptom surveys, cognitive tests, and magnetic resonance imaging scans at the beginning, middle, and end of treatment.",[28,64,65,29,66],"Long COVID Syndrome","Long COVID-19 Syndrome","PASC Post Acute Sequelae of COVID 19","2025-07-11",{"date":69,"type":41},"2025-07-15",{"date":71,"type":41},"2025-07-07",{"date":73,"type":21},"2029-06-30",{"name":75,"class":48},"University of New Mexico",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100586138","from-inflammation-to-remodelling-towards-personalized-diagnosis-in-post-acute-sequelae-of-covid-19-100586138","NCT06911476","From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19","From Inflammation Biomarkers to Remoddeling (FAPI PET\u002FCT) Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19","LIBERATE","Inclusion Criteria:\n\n\\- Self-reported complaints of dyspnea or fatigue \\> 3 months after SARS-CoV-2 infection confirmed with PCR, serology test or COVID-19 Reporting and Data System (CO-RADS) score 4\u002F5.\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent.\n* History of claustrophobia or feeling of inability to tolerate supine position for the PET\u002FCT scans.\n* Individuals who are pregnant or currently breastfeeding are not eligible to participate",true,"20 Years",{"count":60,"type":21},"OBSERVATIONAL","Rationale: The diagnosis and pathogenesis of long COVID remains unknown. We have previously shown that \\[68Ga\\]FAPI Positron Emission Tomography-Computed Tomography (PET\u002FCT) imaging shows potential for diagnosis and molecular understanding of this syndrome. We have previously shown that fibroblast activation protein (FAP) can be imaged in the lung, muscle and nasopharynx of long COVID patients (with dyspnea and fatigue). However, these preliminary data are derived from a selective group of patients with long COVID after critical COVID-19. We aim to explore the generalizability of these findings in patients with long COVID with dyspnea and fatigue, irrespective of the severity of their acute SARS-CoV-2 infection.\n\nPrimary objective: To assess if pulmonary fibroblast activity, measured by \\[68Ga\\]FAPI-46 PET\u002FCT, is higher in patients with current long COVID dyspnea and fatigue compared to patients with resolved complaints.\n\nStudy design: This is a ZonMw funded single centre prospective observational cohort study of long COVID-19 patients with dyspnea and fatigue.\n\nStudy population: We will recruit 60 adult long COVID patients (aged \\>20 years) of which 30 have complaints of dyspnea and fatigue and compare them to 30 patients with resolved complaints and healthy controls.\n\nMain study parameters\u002Fendpoints: The primary endpoint is FAP expression in the lung measured by \\[68Ga\\]FAPI-46 PET\u002FCT. Secondary endpoints are the expression of FAP in other tissues (muscle) and the relation between FAP and inflammation and remodelling biomarkers in various biological samples (e.g. serum\u002Fnasal epithelium).\n\nStudy procedures: In a single visit day the following data and samples will be collected: questionnaires, a lung function test, 6-minute walking test, blood samples, nose swabs, \\[68Ga\\]FAPI PET\u002FCT scan and HRCT scan. When increased \\[68Ga\\]FAPI uptake is measured in the muscles a muscle biopsy will be performed as well.",[66,28,90,29,91,92,93,94,95],"Long Covid-19","FAPI","FAP","Fibroblast Activation Protein Inhibitor","Fibroblast","Restrictive Lung Disease","NOT_YET_RECRUITING","2025-04-03",{"date":99,"type":41},"2025-04-04",{"date":101,"type":21},"2025-05",{"date":103,"type":21},"2025-12",{"name":105,"class":48},"University Medical Center Groningen",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":49},"100583990","osteopathic-manipulative-therapy-effects-on-post-acute-sequelae-of-covid-19-pasc-or-long-covid-100583990","NCT06883513","Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID","Osteopathic Manipulative Therapy(OMT) Effects on Post-Acute Sequalae of COVID-19(PASC)","Inclusion Criteria:\n\n* \\- Individuals must claim they have had a prior positive SARS-CoV-2 test at least 6-weeks before the consenting process to proceed with the study\n* Individuals must claim they have at least one of the following symptoms greater than 6-weeks post infection that is affecting their daily life(these symptoms correlate with the SBQ™-LC):\n\nSymptoms of Long Covid Inclusion Criteria:\n\n* Shortness of breath or Difficulty Breathing\n* Difficulty with Movement (balance or tremor)\n* Muscle Pain or stiffness\n* Changes in sexual desire\n* Worsening Generalized Pain\n* Difficulty with Sleep\n* Changes in Mood (anxiety or depression)\n* Changes in Erectile function (Biological males only)\n* Palpations (irregular heart beats)\n* Altered Taste\n* Changes in your Hair\n* Changes in urination\n* Dizziness\n* Altered Smell\n* Changes in Skin\n* Changes in bowels\n* Fatigue\n* Indigestion\n* Dry or irritated eyes\n* Changes in sweating\n* Difficulty with Cognition (memory or thinking)\n* Stomach Pain\n* Changes in menstruation (Biological females only)\n* Chills or shivering\n\nExclusion Criteria:\n\n* If anyone denies they have any of the above symptoms before consent, they will be excluded from the trial\n\n  * They will also be excluded from the trial if they have suffered any fractured bones in the last 3 months (this will further decrease risk to the patient as the patient will be moved by the physician during the treatment protocol)\n  * Participants who are enrolled in other Long-COVID trials that have an intervention during their participation in this trial will be excluded. However, if they have a history of enrollment in a long-covid trial that has no interventions during this trial, they will not be excluded based on their history of acquiring experimental treatment.",{"count":114,"type":21},20,[116],"NA","This study is investigating the effects of using an Osteopathic Manipulative Therapy (OMT) treatment protocol that was shown to statistically improve smell in individuals suffering from Long-COVID olfactory (smell) dysfunction in a small single-blinded pilot trial conducted during 2021.\n\nThe questions this study is trying to answer are:\n\n1. Does this OMT protocol improve other non-smell related Long-COVID symptoms\n2. Do 2 OMT treatments improve Long-COVID symptoms more than 1 OMT treatment\n\nParticipants will:\n\n1. Week 1: Take an digital survey regarding their Long-COVID symptoms undergo Long-COVID OMT treatment or a placebo treatment\n2. Week 2: Take an digital survey regarding their Long-COVID symptoms then all will undergo Long-COVID OMT treatment\n3. Week 3: Take an digital survey regarding their Long-COVID symptoms\n4. Week 8: Take an digital survey regarding their Long-COVID symptoms",[119,29,64],"Long-COVID",[119,29],"2025-03-17",{"date":123,"type":41},"2025-03-19",{"date":125,"type":21},"2025-05-01",{"date":127,"type":21},"2025-07-03",{"name":129,"class":48},"University of Louisville"]